- Home
- SPFI vs VSTM Comparison
SPFI vs VSTM Comparison
Compare SPFI & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPFI
- VSTM
- Stock Information
- Founded
- SPFI 1941
- VSTM 2010
- Country
- SPFI United States
- VSTM United States
- Employees
- SPFI N/A
- VSTM N/A
- Industry
- SPFI Major Banks
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- SPFI Finance
- VSTM Health Care
- Exchange
- SPFI Nasdaq
- VSTM Nasdaq
- Market Cap
- SPFI 662.8M
- VSTM 598.2M
- IPO Year
- SPFI 2019
- VSTM 2012
- Fundamental
- Price
- SPFI $39.29
- VSTM $9.13
- Analyst Decision
- SPFI Buy
- VSTM Strong Buy
- Analyst Count
- SPFI 3
- VSTM 9
- Target Price
- SPFI $41.67
- VSTM $13.38
- AVG Volume (30 Days)
- SPFI 43.0K
- VSTM 2.6M
- Earning Date
- SPFI 10-22-2025
- VSTM 11-05-2025
- Dividend Yield
- SPFI 1.49%
- VSTM N/A
- EPS Growth
- SPFI 19.09
- VSTM N/A
- EPS
- SPFI 3.20
- VSTM N/A
- Revenue
- SPFI $199,001,000.00
- VSTM $2,137,000.00
- Revenue This Year
- SPFI $13.41
- VSTM $88.50
- Revenue Next Year
- SPFI $6.10
- VSTM $398.66
- P/E Ratio
- SPFI $12.61
- VSTM N/A
- Revenue Growth
- SPFI 7.49
- VSTM N/A
- 52 Week Low
- SPFI $30.01
- VSTM $2.54
- 52 Week High
- SPFI $42.38
- VSTM $11.25
- Technical
- Relative Strength Index (RSI)
- SPFI 45.89
- VSTM 53.24
- Support Level
- SPFI $39.40
- VSTM $9.25
- Resistance Level
- SPFI $40.93
- VSTM $10.04
- Average True Range (ATR)
- SPFI 1.02
- VSTM 0.69
- MACD
- SPFI -0.21
- VSTM -0.16
- Stochastic Oscillator
- SPFI 5.76
- VSTM 12.03
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.